1
|
Zilioli VR, Cencini E, Lorenzo SD, Pezzullo L, Merli M, Rivellini F, Muzi C, Emiliano B, Marcheselli L, Luminari S. Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience. Hematol Oncol 2024; 42:e3273. [PMID: 38661120 DOI: 10.1002/hon.3273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Revised: 04/11/2024] [Accepted: 04/13/2024] [Indexed: 04/26/2024]
Abstract
Few data are known regarding the use of interim positron emission tomography (iPET) after the first two cycles (iPET2) of chemotherapy in treatment-naïve classical Hodgkin lymphoma (cHL) in routine clinical practice, and about the real-life adoption of intensification strategies for iPET positive patients. We conducted a multicenter retrospective study on cHL to investigate the use of iPET in the real-life setting, its prognostic role and outcomes of patients early shifted to intensification. Six hundreds and forty-one patients were enrolled (62% had advanced stage). iPET2 was positive in 89 patients (14%) including 8.7% and 17% early and advanced stage patients, respectively (p = 0.003). Among iPET 2 positive cases treatment was immediately modified in 19 cases; in 14 cases treatment was modified after an additional positive iPET4. Overall 56 iPET2 positive patients never received intensified therapies. Most frequently used intensified therapy was autologous stem cell transplantation followed by BEACOPP. After a median follow-up of 72 months, the 5-year progression-free survival (PFS) was 82% with iPET2 positive patients showing a worse PFS compared with iPET2 negative cases: 31% versus 85%. Focusing on advanced stage patients with a positive iPET2, the 5-year PFS was 59% for patients shifted to intensified therapy at any time point versus 61% for patients who never received intensified therapy. Our study confirmed the higher curability of naïve cHL patients in a real-world setting, and the prognostic role of iPET2 in this setting. A poor adherence to response-adapted strategy which however did not translate into a difference in patient outcomes.
Collapse
Affiliation(s)
| | - Emanuele Cencini
- Hematology, Azienda Ospedaliera Universitaria Senese & University of Siena, Siena, Italy
| | - Sonya De Lorenzo
- U.O.C. Ematologia e T.M.O., AORN "S.G. Moscati", Avellino, Italy
| | - Luca Pezzullo
- U.O.C. di Ematologia con Trapianto di Midollo Osseo, A.U.O. "San Giovanni di Dio e Ruggi D'Aragona", Salerno, Italy
| | - Michele Merli
- Ospedale di Circolo e Fondazione Macchi, Varese, Italy
- Hematology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - Flavia Rivellini
- U.O.C. Ematologia e T.M.O., AORN "S.G. Moscati", Avellino, Italy
| | - Cristina Muzi
- Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Barbieri Emiliano
- Doctorate School of Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | | | - Stefano Luminari
- Hematology Unit, Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale - IRCCS, University of Modena and Reggio Emilia, Reggio Emilia, Italy
- Chimomo Department, University of Modena and Reggio Emilia, Reggio Emilia, Italy
| |
Collapse
|
2
|
Russell J, Collins A, Fowler A, Karanth M, Saha C, Docherty S, Padayatty J, Maw K, Lentell I, Cooke L, Hodson A, Shah N, Sadullah S, Grigoropoulos N, Qian W, Kirkwood AA, Uttenthal BJ, Johnson P, Follows GA. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Ann Hematol 2021; 100:1049-1058. [PMID: 33641019 PMCID: PMC7960595 DOI: 10.1007/s00277-021-04460-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Accepted: 02/10/2021] [Indexed: 10/31/2022]
Abstract
Treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or escalated(e)-BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone) remains the international standard of care for advanced-stage classical Hodgkin lymphoma (HL). We performed a retrospective, multicentre analysis of 221 non-trial ("real-world") patients, aged 16-59 years, diagnosed with advanced-stage HL in the Anglia Cancer Network between 2004 and 2014, treated with ABVD or eBEACOPP, and compared outcomes with 1088 patients in the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) trial, aged 18-59 years, with median follow-up of 87.0 and 69.5 months, respectively. Real-world ABVD patients (n=177) had highly similar 5-year progression-free survival (PFS) and overall survival (OS) compared with RATHL (PFS 79.2% vs 81.4%; OS 92.9% vs 95.2%), despite interim positron-emission tomography-computed tomography (PET/CT)-guided dose-escalation being predominantly restricted to trial patients. Real-world eBEACOPP patients (n=44) had superior PFS (95.5%) compared with real-world ABVD (HR 0.20, p=0.027) and RATHL (HR 0.21, p=0.015), and superior OS for higher-risk (international prognostic score ≥3 [IPS 3+]) patients compared with real-world IPS 3+ ABVD (100% vs 84.5%, p=0.045), but not IPS 3+ RATHL patients. Our data support a PFS, but not OS, advantage for patients with advanced-stage HL treated with eBEACOPP compared with ABVD and suggest higher-risk patients may benefit disproportionately from more intensive therapy. However, increased access to effective salvage therapies might minimise any OS benefit from reduced relapse rates after frontline therapy.
Collapse
Affiliation(s)
- James Russell
- Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
| | - Angela Collins
- Department of Haematology, Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Colney Lane, Norwich, NR4 7UY UK
| | - Alexis Fowler
- Department of Haematology, Peterborough City Hospital, Peterborough and Stamford Hospitals NHS Foundation Trust, Edith Cavell Campus, Bretton Gate, Peterborough, PE3 9G UK
| | - Mamatha Karanth
- Department of Haematology, West Suffolk Hospital, West Suffolk NHS Trust, Hardwick Lane, Bury St Edmunds, IP33 2QZ UK
| | - Chandan Saha
- Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
| | - Suzanne Docherty
- Department of Haematology, Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Colney Lane, Norwich, NR4 7UY UK
| | - Joseph Padayatty
- Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
| | - Kyaw Maw
- Department of Haematology, James Paget University Hospital, James Paget University Hospitals NHS Foundation Trust, Lowestoft Road, Gorleston-on-Sea, Great Yarmouth, NR31 6LA UK
| | - Isabel Lentell
- Department of Haematology, West Suffolk Hospital, West Suffolk NHS Trust, Hardwick Lane, Bury St Edmunds, IP33 2QZ UK
| | - Lisa Cooke
- Department of Haematology, The Queen Elizabeth Hospital, King’s Lynn NHS Foundation Trust, Gayton Rd, King’s Lynn, PE30 4ET UK
| | - Andrew Hodson
- Department of Haematology, Ipswich Hospital, Ipswich Hospital NHS Trust, Heath Rd, Ipswich, IP4 5PD UK
| | - Nimish Shah
- Department of Haematology, Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Colney Lane, Norwich, NR4 7UY UK
| | - Shalal Sadullah
- Department of Haematology, James Paget University Hospital, James Paget University Hospitals NHS Foundation Trust, Lowestoft Road, Gorleston-on-Sea, Great Yarmouth, NR31 6LA UK
| | - Nicholas Grigoropoulos
- Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
| | - Wendi Qian
- Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
| | - Amy A. Kirkwood
- Cancer Research UK and University College London Cancer Trials Centre, University College London, 90 Tottenham Court Road, London, W1T 4TJ UK
| | - Benjamin J. Uttenthal
- Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
| | - Peter Johnson
- Cancer Research UK Centre, University of Southampton, University Road, Southampton, SO17 1BJ UK
| | - George A. Follows
- Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ UK
| |
Collapse
|
3
|
Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol 2021; 8:e278-e288. [PMID: 33770483 DOI: 10.1016/s2352-3026(21)00029-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Revised: 01/24/2021] [Accepted: 02/01/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND To improve the long-term tumour control in early, unfavourable Hodgkin Lymphoma, the German Hodgkin Study Group (GHSG) HD14 trial compared four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with an intensified chemotherapy regimen consisting of two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP) plus two cycles of ABVD. The final analysis of the trial showed a significant advantage in terms of freedom from treatment failure (difference 7·2% [95% CI 3·8-10·5] at 5 years) for patients who received two cycles of escalated BEACOPP and two cycles of ABVD. However, there was no difference in overall survival between the two groups. To evaluate long-term efficacy and toxicity of this strategy, we did a follow-up analysis. METHODS Patients aged 18-60 years with performance status of 2 or less and primary diagnosis of early, unfavourable Hodgkin lymphoma (all histologies) were included in an international, randomised, open-label, phase 3 trial. Patients were randomly assigned to receive four cycles of ABVD (ABVD group) or two cycles of escalated BEACOPP and two cycles of ABVD (2 + 2 group), both groups also received 30 Gy involved field radiotherapy. The ABVD dosing regimen was doxorubicin 25 mg/m2 (days 1 and 15), bleomycin 10 mg/m2 (days 1 and 15), vinblastine 6 mg/m2 (days 1 and 15), and dacarbazine 375 mg/m2 (days 1 and 15), repeated on day 29. The escalated BEACOPP dosing regimen was cyclophosphamide 1250 mg/m2 (day 1), doxorubicin 35 mg/m2 (day 1), etoposide 200 mg/m2 (days 1-3), procarbazine 100 mg/m2 (days 1-7), prednisone 40 mg/m2 (days 1-14), vincristine 1·4 mg/m2 (day 8; maximum 2 mg), and bleomycin 10 mg/m2 (day 8), repeated on day 22. After closure of the ABVD group according to prespecified rules, patients were assigned to receive two cycles of escalated BEACOPP and two cycles of ABVD (non-randomised 2 + 2 group), which continued until the end of the predefined 5-year recruitment period. In this prespecified long-term follow-up analysis, we aimed to evaluate the secondary endpoints progression-free survival, overall survival, and long-term toxicity. To this end, we did a descriptive intention-to-treat analysis of all qualified HD14 patients and on the predefined subsets of randomised qualified HD14 patients and patients in the non-randomised 2 + 2 group. The trial was registered on the International Standard Randomised Controlled Trial database, 04761296. FINDINGS Between Jan 28, 2003, and Dec 29, 2009, 1686 patients were randomly assigned to the ABVD group (847 [50·2%] patients) and the 2 + 2 group (839 [49·8%] patients). 370 additional patients were recruited to the non-randomised 2 + 2 group. 1550 (92%) randomly assigned patients (median observation time 112 months [IQR 80-132]) and 339 (92%) patients in the non-randomised 2 + 2 group (median observation time 74 months [58-100]) were included in the qualified analysis set. 10-year overall survival in the randomly assigned patients was 94·1% (95% CI 92·0-95·7) for the ABVD group and 94·1% (91·8-95·7) for the 2 + 2 group (HR 1·0 [95% CI 0·6-1·5]; p=0·88). 8-year overall survival in the non-randomised 2 + 2 group was 95·1% (95% CI 91·6-97·2). 10-year progression-free survival in the randomly assigned patients was 85·6% (95% CI 82·6-88·1) for the ABVD group and 91·2% (88·4-93·3) for the 2 + 2 group (HR 0·5% [95% CI 0·4-0·7]; p=0·0001), accounting for a significant difference of 5·6% (95% CI 1·9-9·2) favouring the 2 + 2 group (p=0·0001). In the non-randomised 2 + 2 group, 8-year progression-free survival was 94·5% (95% CI 91·1-96·6). Standardised incidence ratios of second primary malignancies were similar between the ABVD group (2·3 [95% CI 1·6-3·1]) and the 2 + 2 group (2·5 [1·8-3·4]; Gray's p=0·80). Standardised incidence ratio of second primary malignancies was 3·1 (95% CI 1·7-5·0) in the non-randomised 2 + 2 group. INTERPRETATION This long-term analysis confirms superior tumour control in the 2 + 2 group compared with the ABVD group without translating into an overall survival difference. At longer follow-up, there is no difference regarding second primary malignancies between groups. In conclusion, the 2 + 2 regimen spares a significant number of patients from the burden of relapse and additional treatment without increased long-term toxicity. FUNDING Deutsche Krebshilfe eV and Swiss Federal Government.
Collapse
Affiliation(s)
- Sarah Gillessen
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Cancer Center Cologne Essen-Partner Site Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Annette Plütschow
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Cancer Center Cologne Essen-Partner Site Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Michael Fuchs
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Cancer Center Cologne Essen-Partner Site Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Jana Markova
- Third Faculty of Medicine, Charles University Prague, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Richard Greil
- Department of Internal Medicine III, University Hospital Salzburg, Salzburg, Austria
| | - Max S Topp
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
| | - Julia Meissner
- Fifth Department of Internal Medicine, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany
| | - Josée M Zijlstra
- Vrije Universiteit, University Medical Center, Amsterdam, Netherlands
| | - Dennis A Eichenauer
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Cancer Center Cologne Essen-Partner Site Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Paul J Bröckelmann
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Cancer Center Cologne Essen-Partner Site Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Volker Diehl
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Peter Borchmann
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Cancer Center Cologne Essen-Partner Site Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Andreas Engert
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Cancer Center Cologne Essen-Partner Site Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany
| | - Bastian von Tresckow
- German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Germany; Department of Hematology and Stem Cell Transplantation and Cancer Center Cologne Essen-Partner Site Essen, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
| |
Collapse
|
4
|
Reid JH, Marini BL, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Crit Rev Oncol Hematol 2020; 148:102897. [PMID: 32109715 DOI: 10.1016/j.critrevonc.2020.102897] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2019] [Revised: 01/06/2020] [Accepted: 02/03/2020] [Indexed: 01/12/2023] Open
Abstract
Advanced classical Hodgkin lymphoma (cHL) is a rare lymphoid disease characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells. Each year, cHL accounts for 0.5% of all new cancer diagnoses and about 80% are diagnosed with advanced stage disease. Given the significant improvement in cure rates, the focus of treatment has shifted towards minimization of acute and long-term toxicities. PET-adapted strategies have largely been adopted as standard of care in the United States in an attempt to balance toxicities with adequate lymphoma control. However, the appropriate upfront chemotherapy regimen (ABVD versus eBEACOPP) remains controversial.
Collapse
Affiliation(s)
- Justin H Reid
- Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine and the University of Michigan College of Pharmacy, 1540 E. Hospital Drive, CW 7-251B, Ann Arbor, MI 48109, United States
| | - Bernard L Marini
- Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine and the University of Michigan College of Pharmacy, 1540 E. Hospital Drive, CW 7-251B, Ann Arbor, MI 48109, United States
| | - Victoria R Nachar
- Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine and the University of Michigan College of Pharmacy, 1540 E. Hospital Drive, CW 7-251B, Ann Arbor, MI 48109, United States
| | - Anna M Brown
- Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine and the University of Michigan College of Pharmacy, 1540 E. Hospital Drive, CW 7-251B, Ann Arbor, MI 48109, United States
| | - Sumana Devata
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, United States
| | - Anthony J Perissinotti
- Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine and the University of Michigan College of Pharmacy, 1540 E. Hospital Drive, CW 7-251B, Ann Arbor, MI 48109, United States.
| |
Collapse
|
5
|
Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019; 134:1238-1246. [PMID: 31331918 PMCID: PMC6788007 DOI: 10.1182/blood.2019000719] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 07/03/2019] [Indexed: 01/16/2023] Open
Abstract
Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)-adapted therapy on SWOG S0816. Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 additional cycles of ABVD. Patients not achieving CR on PET2 were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles. After a median follow-up of 5.9 years, a subset of 331 eligible patients with central review of PET2 was analyzed. PET2 was negative in 82% and positive in 18%. For all patients, the estimated 5-year PFS and OS was 74% (95% confidence interval [CI], 69%-79%) and 94% (95% CI, 91%-96%), respectively. For PET2- and PET2+ patients, the 5-year PFS was 76% (95% CI, 70%-81%) and 66% (95% CI, 52%-76%), respectively. Seven (14%) and 6 (2%) patients reported second cancers after treatment with eBEACOPP and ABVD, respectively (P = .001). Long-term OS of HL patients treated on S0816 remains high. Nearly 25% of PET2- patients experienced relapse events, demonstrating limitations ABVD therapy and of the negative predictive value of PET2. In PET2+ patients who received eBEACOPP, PFS was favorable, but was associated with a high rate of second malignancies compared with historical controls. Our results emphasize the importance of long-term follow-up, and the need for more efficacious and less toxic therapeutic approaches for advanced-stage HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00822120.
Collapse
Affiliation(s)
- Deborah M Stephens
- Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT
| | - Hongli Li
- SWOG Statistical Center, Seattle, WA
| | - Heiko Schöder
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | | - Nancy L Bartlett
- Oncology Division, Washington University in St. Louis, St. Louis, MO
| | - Andrew M Evens
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | | | - Paul M Barr
- Division of Hematology/Oncology, University of Rochester, Rochester NY
| | - Michael V Knopp
- Division of Hematology, The Ohio State University, Columbus, OH
| | | | | | - Brad S Kahl
- Oncology Division, Washington University in St. Louis, St. Louis, MO
| | - Sonali M Smith
- Section of Hematology/Oncology, University of Chicago, Chicago, IL
| | | |
Collapse
|
6
|
Faivre G, Butler MJ, Le I, Brenner A. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. Clin Lymphoma Myeloma Leuk 2019; 19:665-669. [PMID: 31351990 DOI: 10.1016/j.clml.2019.05.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Accepted: 05/21/2019] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. Whole-brain radiotherapy and autologous stem cell transplantation carry increased toxicity in patients older than 60 years of age, which might outweigh the benefits in this group. Temozolomide (TMZ) has established antineoplastic activity in the central nervous system in other disease states, with a favorable toxicity profile. PATIENTS AND METHODS We report efficacy and tolerability in a series of 10 patients treated off-label with TMZ maintenance after completion of R-MPV (rituximab, methotrexate, procarbazine and vincristine) treatment for or primary diagnosed PCNSL. RESULTS Median progression-free survival (PFS) was 57 months, 2-year PFS was 67%, and 5-year PFS was 33%. Median overall survival (OS) was 63 months, 2-year OS was 88%, and 5-year OS was 57%. TMZ was generally well tolerated, with the most common toxicity of Grade 3 or higher being thrombocytopenia in 3 patients (30%). CONCLUSION These outcomes suggest that TMZ might have activity for maintenance in elderly patients with PCNSL, when more aggressive treatments are contraindicated.
Collapse
Affiliation(s)
- Geraldine Faivre
- Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Matthew James Butler
- Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Isabelle Le
- Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Andrew Brenner
- Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX.
| |
Collapse
|
7
|
Ghoreishi R, Kia M. Chemical reactivity and adsorption properties of pro-carbazine anti-cancer drug on gallium-doped nanotubes: a quantum chemical study. J Mol Model 2019. [PMID: 30689092 DOI: 10.1007/s00894-018-3914–2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In this study, we propose new armchair single-walled nanotubes (SWNTs) for stable adsorption, increasing drug delivery performance and decreasing side effects of pro-carbazine (Pro-CB) anti-cancer in the framework of B3LYP/6-31 g*/Lanl2DZ level of theory. Indeed, doping gallium (Ga) metal in SWNTs is naturally followed by changing of geometry, increasing dipole moment, and creating one site with high reactivity in order to better adsorption of the drug molecule. Chemical reactivity descriptors show that SWNTs and Pro-CB have electrophile and nucleophile roles in interaction, respectively. More importantly, high local and dual softness in Ga-doped SWNTs indicate improvement of drug adsorption. Parallel and perpendicular complexes result from their interaction in the N and the O sites. Negative values of binding energy (Ebind) show that composed complexes are energetically stable especially in the O site in comparison with the N site. On the other hand, more negative value of the Ebind in SWCNTs shows that these nanotubes are more effective for drug adsorption than their boron nitride counterparts. Graphical abstract The Ga dopping results in reducing of HOMO-LUMO gap and increasing charge transfer between SWNTs and Pro-CB, and formation better complex, especially SWCNT.
Collapse
Affiliation(s)
- Reza Ghoreishi
- Department of Chemistry, Rasht Branch, Islamic Azad University, Rasht, Iran
| | - Majid Kia
- Department of Chemistry, Rasht Branch, Islamic Azad University, Rasht, Iran.
| |
Collapse
|
8
|
Levis A, Pietrasanta D, Anselmo AP, Ambrosetti A, Bertini M. Treatment of Elderly Hodgkin's Lymphoma Patients. The Experience of the Italian Lymphoma Intergroup. Tumori 2018; 88:S29-31. [PMID: 11989917 DOI: 10.1177/030089160208800109] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Alessandro Levis
- Haematology Department, Ospedale SS Antonio e Biagio, Alessandria
| | | | | | | | | |
Collapse
|
9
|
Abstract
A retrospective analysis of 118 patients with non-Hodgkin's lymphomas who received one or more drugs of single agent chemotherapy was conducted to determine the relationship between the histopathologic category of lymphoma, based on the classification proposed by Rappaport et al., and the results (type of regression and survival) of sequential chemotherapy. In 96/118 cases, slides were available for histopathologic reclassification. Patients were selected according to the following criteria: chemotherapy with single agents administered in sequence (e.g. alkylating agents, vincristine, adriamycin, bleomycin); change in drug administration only after an adequate course and either no response or clinical resistance after prior regression; measurable disease; performance status greater than 40. Prior to chemotherapy 66 patients had diffuse (extranodal) disease, 39 adenopathies above and below the diaphragm, and 13 adenopathies only above or below the diaphragm. 49/118 patients were pretreated with radiotherapy. The data were most complete for alkylating agents which were administered as a single agent in 93 patients. Complete remission (CR) plus partial remission (PR) greater than 50% occurred in 39% of patients with lymphocytic lymphoma, in 39% with histiocytic and in 50% with mixed type lymphoma (table 4). This type of response was observed with all drugs in 70% of nodular lymphomas and in 36% of diffuse lymphomas (table 7). The overall response rate to adriamycin was 75% in nodular lymphomas, and 55% in diffuse lymphomas. These data were 40% and respectively 14% after treatment with bleomycin. Median survival of all non-Hodgkin's lymphomas was 16.2 months (fig. 1); median survival was 23.4 months for nodular lymphomas and 17.4 months for diffuse lymphomas (fig. 2). Among nodular lymphomas, no significant differences were observed between nodular histiocytic and nodular lymphocytic well differentiated (fig. 3). Diffuse lymphocytic well differentiated lymphomas showed better survival in comparison to diffuse lymphocytic poorly differentiated, diffuse histiocytic and diffuse undifferentiated types (fig. 4). Patients responding to 2 drugs or more showed a better median survival (66 months) than those responding only to one drug (22.4 months) and unresponsive patients (10.2 months) (fig. 5). This study confirms most of the data reported by the Stanford group and emphasizes the need to employ a more deteailed histopathologic classification such as that proposed by Rappaport et al. Although this retrospective analysis has a number of drawbacks, it does provide, in terms of survival, a measurable indication that the responsiveness to at least two drugs is associated with better survival in non-Hodgkin's lymphomas than little or no responsiveness.
Collapse
|
10
|
Abate G, Comella P, Di Pietro N, Ganzina F, Pergola M, Silvestro P, Basso A, Salvatore M, Zarrilli D. Epirubicin in Combination Chemotherapy in the Treatment of Advanced Stage Non-Hodgkin's Lymphomas. Tumori 2018; 73:43-7. [PMID: 3469805 DOI: 10.1177/030089168707300108] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
From April 1981 to May 1984, 23 patients with advanced non-Hodgkin's lymphomas were treated with CEOP (cyclophosphamide, epirubicin, vincristine, and prednisone) or OEPP (vincristine, epirubicin, procarbazine, and prednisone) combination chemotherapy. CR was achieved in 58 % and PR in 31 % of the patients, giving an overall response rate of 89 %. Nine of 15 (60 %) previously untreated patients with unfavorable histology obtained a CR and 5 a PR. Median relapse-free survival was 33 months; median overall survival has not yet been reached, and the probability of survival for CRs was 91 % after 54 months of follow-up. Acute toxicity was quite acceptable, and chronic cardiac toxicity was detected in 6 patients only. In conclusion, epirubicin used in combination chemotherapies induced durable remissions and prolonged survivals in advanced non-Hodgkin's lymphomas.
Collapse
|
11
|
Abstract
Antibody-dependent cellular cytotoxicity mediated by K cells against chicken erythrocytes was measured in 113 patients with malignant lymphoreticular disorders and compared with 230 controls. The results were expressed as the specific cytotoxicity of a fixed number of cells and also by cytotoxic capacity, which measures the number of cytolytic units in 1 ml of blood. The values for cytotoxic capacity were normal in the group of untreated patients with non-Hodgkin's lymphomas, multiple myeloma or chronic lymphocytic leukemia and in most of the patients with Hodgkin's disease or acute lymphoblastic leukemia. However, decreased specific cytotoxicity was observed in these same lymphoid leukemia patients, which may be due to dilution of effector cells. The effect of chemotherapy in reducing K-cell activity is more evident in patients with multiple myeloma, followed by patients with Hodgkin's disease, and finally by patients with non-Hodgkin's lymphomas. No case of K-cell neoplastic disease was observed in this series.
Collapse
|
12
|
Monfardini S, Tancini G, Gasparini M, Bonadonna G. Response and Survival in Hodgkin's Disease after Sequential Chemotheraphy Employing a Single Agent. Tumori 2018; 59:45-56. [PMID: 4122634 DOI: 10.1177/030089167305900105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The therapeutic results obtained in 59 patients with advanced Hodgkin's disease treated from 1964 to 1969 with sequential chemotherapy employing a single agent are reported. The main sequence was alkylating agent first, vinblastine second and procarbazine third. Complete plus partial remission (> 50 %) ranged from a minimum of 37 % for patients treated with procarbazine to a maximum of 42 % for those given vinblastine. The median duration of response ranged from 4 to 5 months. Overall median survival from institution of chemotherapy was 24 months. Patients (26 cases) responding to 2 or more drugs showed a median survival of 40 months, which was statistically greater than that observed in an equal number of cases responding only to one drug (13 months) and than that of 7 patients unresponsive to all drugs (9 months). It is concluded from this retrospective study that survival in advanced Hodgkin's disease is longer in patients responding to at least two drugs that in patients responding less or not at all.
Collapse
|
13
|
Tirelli U, Zagonel V, Volpe R, Trovò MG, Carbone A. Non-Hodgkin's Lymphoma in the Elderly: A Retrospective Evaluation of Toxicity Related to Aggressive vs. Conservative Treatments. Tumori 2018; 74:433-8. [PMID: 2460983 DOI: 10.1177/030089168807400410] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The outcome of 70 elderly patients aged 65 years or more (median, 71 years) with non-Hodgkin's lymphoma (NHL) treated between 1973 and 1981 with aggressive (AM) or conservative modalities (CM) was retrospectively evaluated. A significantly higher incidence of lethal and severe toxicity was observed in patients treated with AM than in those treated with CM (32 % vs 3 %, p < 0.01), with 10 % treatment related deaths in the AM group. Only 56 % of the deaths were attributed to NHL; other major causes were treatment-related deaths, infection and cardiac diseases. No significant difference in response and survival was found between AM and CM groups (complete remission rates were 35 % vs 42 %, and 10 year survival rates were 31 % vs 19 %, respectively), but the prevalence of stages III-IV in patients treated with AM makes these results meaningless. Prospective randomized trials with AM vs CM are clearly needed in elderly patients with advanced unfavorable NHL.
Collapse
Affiliation(s)
- U Tirelli
- Divisione di Oncologia Medica, Centro di Riferimento Oncologico, Aviano, Italia
| | | | | | | | | |
Collapse
|
14
|
Demicheli R, Bonciarelli G, Jirillo A, Lonardi F, Balli M. Bleomycin, Vincristine, Mitomycin and Cisplatin Alternated with Cyclophosphamide, 4'-Epidoxorubicin and Procarbazine in Advanced Non-small-cell Lung Cancer. Tumori 2018; 74:563-6. [PMID: 2464223 DOI: 10.1177/030089168807400512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Thirty-eight patients with histologically confirmed non-small-cell lung cancer were treated with bleomycin, vincristin, mitomycin and cisplatin (BOMP) alternated with cyclophosphamide, 4'-epidoxorubicin and procarbazine (CEP). Twenty patients were randomized to start the treatment with BOMP and 18 with CEP. Patients underwent a median of 4 cycles (range, 1-8). The overall response rate was 36% with 2 clinical complete responses. The median duration of response was 6.5 months, the median survival time was 7.5 months, and 37% of patients survived for more than one year. The comparison between the two arms of this study and between this study and a previous investigation on the effectiveness of BOMP suggests that CEP regimen added to BOMP does not significantly improve patient outcome.
Collapse
Affiliation(s)
- R Demicheli
- Divisione di Radioterapia e Oncologia, ULSS 28, Legnago, Verona, Italia
| | | | | | | | | |
Collapse
|
15
|
Schirm S, Engel C, Loibl S, Loeffler M, Scholz M. Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. J Cancer Res Clin Oncol 2018; 144:343-358. [PMID: 29103159 PMCID: PMC5794835 DOI: 10.1007/s00432-017-2540-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Accepted: 10/24/2017] [Indexed: 02/07/2023]
Abstract
PURPOSE Although G-CSF is widely used to prevent or ameliorate leukopenia during cytotoxic chemotherapies, its optimal use is still under debate and depends on many therapy parameters such as dosing and timing of cytotoxic drugs and G-CSF, G-CSF pharmaceuticals used and individual risk factors of patients. METHODS We integrate available biological knowledge and clinical data regarding cell kinetics of bone marrow granulopoiesis, the cytotoxic effects of chemotherapy and pharmacokinetics and pharmacodynamics of G-CSF applications (filgrastim or pegfilgrastim) into a comprehensive model. The model explains leukocyte time courses of more than 70 therapy scenarios comprising 10 different cytotoxic drugs. It is applied to develop optimized G-CSF schedules for a variety of clinical scenarios. RESULTS Clinical trial results showed validity of model predictions regarding alternative G-CSF schedules. We propose modifications of G-CSF treatment for the chemotherapies 'BEACOPP escalated' (Hodgkin's disease), 'ETC' (breast cancer), and risk-adapted schedules for 'CHOP-14' (aggressive non-Hodgkin's lymphoma in elderly patients). CONCLUSIONS We conclude that we established a model of human granulopoiesis under chemotherapy which allows predictions of yet untested G-CSF schedules, comparisons between them, and optimization of filgrastim and pegfilgrastim treatment. As a general rule of thumb, G-CSF treatment should not be started too early and patients could profit from filgrastim treatment continued until the end of the chemotherapy cycle.
Collapse
Affiliation(s)
- Sibylle Schirm
- Medical Faculty, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Haertelstraße 16-18, 04107 Leipzig, Germany
| | - Christoph Engel
- Medical Faculty, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Haertelstraße 16-18, 04107 Leipzig, Germany
| | - Sibylle Loibl
- German Breast Group, c/o GBG Forschungs GmbH, Martin-Behaim-Straße 12, 63263 Neu-Isenburg, Germany
| | - Markus Loeffler
- Medical Faculty, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Haertelstraße 16-18, 04107 Leipzig, Germany
| | - Markus Scholz
- Medical Faculty, Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Haertelstraße 16-18, 04107 Leipzig, Germany
| |
Collapse
|
16
|
Okamoto S, Tanaka M, Goto T, Nakashima M, Nagura E. [Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System]. Gan To Kagaku Ryoho 2017; 44:2109-2112. [PMID: 29361628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We studied the clinical effects of high-dose methotrexate(HD-MTX)combined with rituximab and vincristine in 5 elderly patients, aged 65-83 years, with diffuse large B-cell lymphoma of the central nervous system(DLBCL CNS). Patients aged 65- 71 years were given 3.0 g/m2 of HD-MTX, while patients aged 75-83 years were given 1.5 g/m2 of the drug. All patients showed responses; 1 CR and 1 PR in MTX 3.0 g/m2 group, and 2 CRs and 1 PR in MTX 1.5 g/m2 group.
Collapse
|
17
|
Abstract
BACKGROUND Recurrent high-grade glioma (HGG) carries an extremely poor prognosis. There is no current standard of care or guideline-based recommendations. Nitrosourea-based multidrug chemotherapy or PCV - procarbazine, lomustine (CCNU) and vincristine - is one of the treatment options at recurrence. There has been no meta-analysis which looks at the benefits and harms of PCV chemotherapy in adults with recurrent HGG. OBJECTIVES To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma. To investigate whether predefined subgroups of people benefit more or less from chemotherapy. SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 4, 2017), MEDLINE (1946 to 22 May 2017), and Embase (1980 to 22 May 2017). We searched trial registries including the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; apps.who.int/trialsearch) and the National Institutes of Health (NIH; ClinicalTrials.gov). We searched the reference lists of all identified studies; the electronic table of contents of the Journal of Neuro-Oncology (1983 to 2016) and Neuro-Oncology (1999 to 2016); and conference abstracts from the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO 2004 to 2016). We also searched unpublished grey literature and other regional databases. There were no language restrictions. SELECTION CRITERIA Randomised controlled trials (RCTs), quasi-randomised trials (QRCTs), or controlled clinical trials (CCTs) where PCV was used to treat adults with recurrent HGG. Comparison arm included no chemotherapy, other second line chemotherapy or best supportive care. DATA COLLECTION AND ANALYSIS Two review authors extracted the data and undertook a 'Risk of bias' assessment and critical appraisal of the studies. MAIN RESULTS We identified two RCTs meeting our inclusion criteria. The two trials tested different comparisons.One RCT included 35 participants and compared PCV with 'eight drugs in one day' multidrug chemotherapy, which is a combination of drugs with different mechanisms of action. Median survival was 6 months for the PCV group and 6.5 months for the 'eight drugs in one day' group. Adverse event outcomes were not graded or quantified. Progression-free survival (PFS) and quality of life (QoL) were not described in the methods and were not an outcome of interest. The sample size in this study was small, which lead to insufficient statistical power to detect clinical differences. According to the GRADE approach we judged the quality of evidence to be low for survival outcome and very low for chemotherapy toxicityThe second multi-institutional RCT included 447 participants and compared PCV with Temozolomide (TMZ). Participants were randomised into three arms to receive PCV, and two different regimens of TMZ in a 2:1:1 ratio at first recurrence. The trial reported a median overall survival of 6.7 months and 7.2 months for the PCV and TMZ group respectively. It reported a PFS of 3.6 months for the PCV group and 4.7 months for the TMZ group. There was no observed difference of effect on overall survival (hazard ratio (HR) 0.91, 95% CI 0.74 to 1.11; P = 0.35) or PFS (HR 0.89, 95% CI 0.73 to 1.08; P = 0.23) in participants receiving PCV or TMZ chemotherapy. The proportion of people with at least one grade 3 or 4 adverse event was not clinically important at 9.2% versus 12.2% in PCV and TMZ arms respectively. Mean QoL scores calculated at baseline, 12 weeks and 24 weeks was 51.9 versus 59.8 favouring TMZ (P = 0.04) which is statistically but not clinically significant and was less than the pre-defined 10 point change for moderate improvement. We judged the GRADE quality of evidence to be moderate for overall survival, PFS, and chemotherapy toxicity and low for QoL. AUTHORS' CONCLUSIONS Evidence is based on a single large trial analysis as the other trial was small, with inadequate power to detect survival difference. Chemotherapy-naive patients with HGG at first recurrence when treated with PCV or TMZ have similar survival and time-to-progression outcomes. Adverse events are similar and QoL scores are statistically but not clinically significant between TMZ and PCV. Further RCTs should be conducted with adequate power following CONSORT guidelines with emphasis on QoL outcomes.
Collapse
Affiliation(s)
- Saurabh Parasramka
- University of Kentucky College of MedicineDepartment of Internal Medicine800 Rose Street, CC447LexingtonKentuckyUSA40536
| | - Goutham Talari
- University of Kentucky College of MedicineDepartment of Internal Medicine800 Rose Street, CC447LexingtonKentuckyUSA40536
| | - Myrna Rosenfeld
- Hospital Clinic /IDIBAPSDepartment of NeurologyVillarroel, 170BarcelonaCatalunyaSpain08036
| | - Jing Guo
- Kentucky ClinicCenter for Health Services Research740 South LimestoneLexingtonUSA40536‐0284
| | - John L Villano
- University of Kentucky College of MedicineDepartment of Internal Medicine800 Rose Street, CC447LexingtonKentuckyUSA40536
| | | |
Collapse
|
18
|
Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2017; 5:CD007941. [PMID: 28541603 PMCID: PMC6481581 DOI: 10.1002/14651858.cd007941.pub3] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND There are two different international standards for the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone) regimen and chemotherapy with ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) regimen. OBJECTIVES To determine the advantages and disadvantages of chemotherapy including escalated BEACOPP compared to chemotherapy including ABVD in the treatment of early unfavourable or advanced stage HL as first-line treatment. SEARCH METHODS We searched for randomised controlled trials in MEDLINE, CENTRAL and conference proceedings (January 1985 to July 2013 and for the update to March 2017) and Embase (1985 to November 2008). Moreover we searched trial registries (March 2017; www.controlled-trials.com, www.clinicaltrialsregister.eu/ctr-search/search, clinicaltrials.gov, www.eortc.be, www.ghsg.org, www.ctc.usyd.edu.au, www.trialscentral.org/index.html) SELECTION CRITERIA: We included randomised controlled trials examining chemotherapy including at least two cycles of escalated BEACOPP regimens compared with chemotherapy including at least four cycles of ABVD regimens as first-line treatment for patients with early unfavourable stage or advanced stage HL. DATA COLLECTION AND ANALYSIS The effect measures we used were hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS) and freedom from first progression.We used risk ratios (RRs) relative risks to analyse harms: treatment-related mortality, secondary malignancies (including myeloid dysplastic syndrome (MDS) or acute myeloid leukaemia (AML)), infertility and adverse events.Quality of life was not reported in any trial, therefore not analysed. Two review authors independently extracted data and assessed quality of trials. MAIN RESULTS We screened 1796 records and identified five eligible trials in total i.e. one trial could be added on the previous review. These trials included only adults (16 to 65 years of age). We included all five trials with 3427 people in the meta-analyses: the HD9 and HD14 trials were co-ordinated in Germany, the HD2000 and GSM-HD trials were performed in Italy and the EORTC 20012 was conducted in Belgium. The overall risk of performance and detection bias was low for overall survival (OS), but was high for other outcomes, as therapy blinding was not feasible. The remaining 'Risk of bias' domains were low and unclear.All trials reported results for OS and progression-free survival (PFS). In contrast to the our first published review (2011) the addition of results from the EORTC 20012 BEACOPP escalated increases OS (3142 participants; HR 0.74 (95% confidence interval (CI) 0.57 to 0.97; high-quality evidence). This means that only 90 (70 to 117) patients will die after five years in the BEACOPP escalated arm compared to 120 in the ABVD arm. This survival advantage is also reflected in an increased PFS with BEACOPP escalated (3142 participants; HR 0.54 (95% CI 0.45 to 0.64); moderate-quality evidence), meaning that after five years only 144 (121 to 168) patients will experience a progress, relapse or death in the BEACOPP escalated arm compared to 250 in the ABVD arm.There is no evidence for a difference for treatment-related mortality (2700 participants, RR 2.15 (95% CI = 0.93 to 4.95), low-quality evidence).Although the occurrence of MDS or AML may increase with BEACOPP escalated (3332 participants, RR 3.90 (95% CI 1.36 to 11.21); low-quality evidence)), there is no evidence for a difference between both regimens for overall secondary malignancies (3332 participants, RR 1.00 (95% CI 0.68 to 1.48), low-quality evidence). However, the observation time of the studies included in the review is too short to be expected to demonstrate differences with respect to second solid tumours which would not be expected to show significance until around 15 years after treatment.We are very uncertain how many female patients will be infertile due to chemotherapy and which arm might be favoured (106 participants, RR 1.37 (95% CI 0.83 to 2.26), very low-quality evidence). This is a very small sample, and the age of the patients was not detailed. No analysis of male fertility was provided.Five trials reported adverse events and the analysis shows that the escalated BEACOPP regimens probably causes more haematological toxicities WHO grade III or IV ((anaemia: 2425 participants, RR 10.67 (95% CI 7.14 to 15.93); neutropenia: 519 participants, RR 1.80 (95% CI 1.52 to 2.13); thrombocytopenia: 2425 participants, RR 18.12 (95% CI 11.77 to 27.92); infections: 2425 participants, RR 3.73 (95% CI 2.58 to 5.38), all low-quality evidence).Only one trial (EORTC 20012) planned to assess quality of life, however, no results were reported. AUTHORS' CONCLUSIONS This meta-analysis provides moderate- to high-quality evidence that adult patients between 16 and 60 years of age with early unfavourable and advanced stage HL benefit regarding OS and PFS from first-line chemotherapy including escalated BEACOPP. The proven benefit in OS for patients with advanced HL is a new finding of this updated review due to the inclusion of the results from the EORTC 20012 trial. Furthermore, there is only low-quality evidence of a difference in the total number of secondary malignancies, as the follow-up period might be too short to detect meaningful differences. Low-quality evidence also suggests that people treated with escalated BEACOPP may have a higher risk to develop secondary AML or MDS. Due to the availability of only very low-quality evidence available, we are unable to come to a conclusion in terms of infertility. This review does for the first time suggest a survival benefit. However, it is clear from this review that BEACOPP escalated may be more toxic that ABVD, and very important long-term side effects of second malignancies and infertility have not been sufficiently analysed yet.
Collapse
Affiliation(s)
- Nicole Skoetz
- University Hospital of CologneCochrane Haematological Malignancies Group, Department I of Internal MedicineKerpener Str. 62CologneGermany50937
| | - Andrea Will
- University Hospital of CologneCochrane Haematological Malignancies Group, Department I of Internal MedicineKerpener Str. 62CologneGermany50937
| | - Ina Monsef
- University Hospital of CologneCochrane Haematological Malignancies Group, Department I of Internal MedicineKerpener Str. 62CologneGermany50937
| | - Corinne Brillant
- University Hospital of CologneCochrane Haematological Malignancies Group, Department I of Internal MedicineKerpener Str. 62CologneGermany50937
| | - Andreas Engert
- University Hospital of CologneDepartment I of Internal MedicineKerpener Str. 62CologneGermany50924
| | - Bastian von Tresckow
- University Hospital of CologneDepartment I of Internal MedicineKerpener Str. 62CologneGermany50924
| | | |
Collapse
|
19
|
Affiliation(s)
- Stephanie E Combs
- Institut für Innovative Radiotherapie (iRT) Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Oberschleißheim, Deutschland.
- Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, Technische Universität München, Klinikum rechts der Isar, Ismaninger Straße 22, 81675, München, Deutschland.
| | - Friederike Schmidt-Graf
- Klinik für Neurologie, Technische Universität München, Klinikum rechts der Isar, Ismaninger Straße 22, 81675, München, Deutschland
| | - Bernhard Meyer
- Klinik für Neurochirurgie, Technische Universität München, Klinikum rechts der Isar, Ismaninger Straße 22, 81675, München, Deutschland
| |
Collapse
|
20
|
Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 2016; 374:1344-55. [PMID: 27050206 PMCID: PMC5170873 DOI: 10.1056/nejmoa1500925] [Citation(s) in RCA: 637] [Impact Index Per Article: 79.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
BACKGROUND Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration and premature death. Early results of this trial showed that treatment with procarbazine, lomustine (also called CCNU), and vincristine after radiation therapy at the time of initial diagnosis resulted in longer progression-free survival, but not overall survival, than radiation therapy alone. We now report the long-term results. METHODS We included patients with grade 2 astrocytoma, oligoastrocytoma, or oligodendroglioma who were younger than 40 years of age and had undergone subtotal resection or biopsy or who were 40 years of age or older and had undergone biopsy or resection of any of the tumor. Patients were stratified according to age, histologic findings, Karnofsky performance-status score, and presence or absence of contrast enhancement on preoperative images. Patients were randomly assigned to radiation therapy alone or to radiation therapy followed by six cycles of combination chemotherapy. RESULTS A total of 251 eligible patients were enrolled from 1998 through 2002. The median follow-up was 11.9 years; 55% of the patients died. Patients who received radiation therapy plus chemotherapy had longer median overall survival than did those who received radiation therapy alone (13.3 vs. 7.8 years; hazard ratio for death, 0.59; P=0.003). The rate of progression-free survival at 10 years was 51% in the group that received radiation therapy plus chemotherapy versus 21% in the group that received radiation therapy alone; the corresponding rates of overall survival at 10 years were 60% and 40%. A Cox model identified receipt of radiation therapy plus chemotherapy and histologic findings of oligodendroglioma as favorable prognostic variables for both progression-free and overall survival. CONCLUSIONS In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 years of age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than among those who received radiation therapy alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00003375.).
Collapse
Affiliation(s)
- Jan C Buckner
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Edward G Shaw
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Stephanie L Pugh
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Arnab Chakravarti
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Mark R Gilbert
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Geoffrey R Barger
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Stephen Coons
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Peter Ricci
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Dennis Bullard
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Paul D Brown
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Keith Stelzer
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - David Brachman
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - John H Suh
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Christopher J Schultz
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Jean-Paul Bahary
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Barbara J Fisher
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Harold Kim
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Albert D Murtha
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Erica H Bell
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Minhee Won
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Minesh P Mehta
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| | - Walter J Curran
- From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.)
| |
Collapse
|
21
|
Meister MT, Voss S, Schwabe D. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab. Pediatr Blood Cancer 2015; 62:2018-20. [PMID: 26109475 DOI: 10.1002/pbc.25621] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 05/13/2015] [Indexed: 02/02/2023]
Abstract
Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.
Collapse
Affiliation(s)
- Michael T Meister
- Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany
| | - Sandra Voss
- Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany
| | - Dirk Schwabe
- Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany
| |
Collapse
|
22
|
Webre C, Shonka N, Smith L, Liu D, De Groot J. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. Anticancer Res 2015; 35:5467-5472. [PMID: 26408710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND While procarbazine with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit. This retrospective study provides a comparison of PC and PCV. PATIENTS AND METHODS Patients diagnosed with AO treated at the M.D. Anderson Cancer Center from June 1, 1993 to October 13, 2009 were selected from the database and were eligible if diagnosed with a primary AO and treated with either PC or PCV at some point. Ninety-seven patients were treated with such chemotherapy before first progression. RESULTS Initial treatment included radiation and chemotherapy (81.4%) or chemotherapy alone (18.6%). Twenty-one patients (21.6%) received PC during primary treatment, while 76 patients (78.4%) received PCV. Eleven patients reported neurotoxicity in the PCV arm vs. none in the PC arm. Out of the 97 patients, 45 were alive at last contact, with a median follow-up of 9.9 years. The median overall survival was 6.5 years (95% confidence interval=4.8-16.7 years), while the median progression-free survival was 2.9 years (95% confidence interval=2.0-6.3 years); these differences were not significant (p=0.61 and p=0.28, respectively). CONCLUSION Initial therapy with PC achieved comparable results to those of PCV with a median follow-up of 9.9 years. Neurotoxicity was more frequent with vincristine. Although selecting only for patients with AO, rather than those with mixed histology, increased the likelihood of selecting for patients with tumors with co-deletions, further studies with correlative co-deletion status are required.
Collapse
Affiliation(s)
- Courtney Webre
- Texas Agricultural and Mechanical College Health Science Center College of Medicine, Bryan, TX, U.S.A
| | - Nicole Shonka
- University of Nebraska Medical Center, Omaha, NE, U.S.A.
| | - Lynette Smith
- University of Nebraska Medical Center, Omaha, NE, U.S.A
| | - Diane Liu
- University of Texas - M.D. Anderson Cancer Center, Houston, TX, U.S.A
| | - John De Groot
- University of Texas - M.D. Anderson Cancer Center, Houston, TX, U.S.A
| |
Collapse
|
23
|
Mashima K, Suzuki S, Mori T, Shimizu T, Yamada S, Hirose S, Okamoto S, Suzuki N. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after treatment for Hodgkin's lymphoma. Int J Hematol 2015; 102:709-12. [PMID: 26243623 DOI: 10.1007/s12185-015-1850-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 07/17/2015] [Accepted: 07/28/2015] [Indexed: 11/25/2022]
Abstract
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a rare central nervous system (CNS) disorder with distinct radiological features. However, CLIPPERS may mimic CNS lymphoma, and several cases in which CLIPPERS occurred premonitory to CNS lymphoma have been reported. We report a 31-year-old man presenting with progressive gait ataxia and the characteristic MRI features of CLIPPERS. He was diagnosed with stage II Hodgkin's lymphoma at the age of 15, and we considered the possibility of newly emerged CNS lymphoma occurring in the immunosuppressive condition after the treatment of Hodgkin's lymphoma. Histological findings showed no evidence of CNS lymphoma and the neurological symptoms were resolved by steroids. Although CLIPPERS developed in the reverse order in this case, CLIPPERS should be considered in different diagnosis for CNS lymphoma.
Collapse
Affiliation(s)
- Kyoko Mashima
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
| | - Shigeaki Suzuki
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
| | - Takehiko Mori
- Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
| | - Toshihiko Shimizu
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
| | - Satoshi Yamada
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
| | - Shigemichi Hirose
- Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan.
| | - Shinichiro Okamoto
- Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
| | - Norihiro Suzuki
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
| |
Collapse
|
24
|
Ganesan P, Rajendranath R, Kannan K, Radhakrishnan V, Ganesan TS, Udupa K, Lakshmipathy KM, Mahajan V, Sundersingh S, Rajaraman S, Krishnakumar R, Sagar TG. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Ann Oncol 2015; 26:1170-1174. [PMID: 25701453 DOI: 10.1093/annonc/mdv077] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Accepted: 02/09/2015] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Combination chemotherapy ABVD (doxorubicin, bleomycin, vinblastine and dacarabazine) cures ∼70% of patients with advanced Hodgkin's lymphoma (aHL, stages IIB, III and IV) while more toxic escalated BEACOPP (EB, combination of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone) increases cure rates to 85%. Patients with a positive interim positron emission tomography-computerized tomography (PET-CT) scan after two cycles (PET-2) of ABVD have very poor outcomes with continued ABVD. Intensifying therapy with EB in PET-2-positive patients ('response-adapted therapy') may improve cure rates, whereas the negative patients can continue ABVD alone. PATIENTS AND METHODS Eligible patients with newly diagnosed aHL received two cycles of ABVD and underwent PET-2 (scored with semi-quantitative 5-point visual criteria, 'Deauville score'). PET-2-negative patients continued four additional cycles of ABVD, whereas PET-2-positive patients received four cycles of EB. A phase II sample size of 50 was estimated keeping the lower and higher proportion of rejection of the event-free survival (EFS) as 70% and 85%, respectively. RESULTS Fifty patients [median age 28 (12-60) years; male : female: 39 : 11; stages: IIB-3 (6%), III-29 (58%) and IV-18 (36%); International Prognostic Score (IPS): 0-3: 34 (68%); 4-7: 16 (32%)] were enrolled; 49 underwent PET-2. Eight (16%) were PET-2-positive, whereas 41 (84%) were negative. Forty-seven were evaluable for EFS and all 50 for overall survival (OS). The 2-year EFS was 76% (95% CI: 68-83) and OS was 88% (95% CI: 82-94). PET-2 was strongly prognostic-2-year EFS, negative versus positive: 82% versus 50%; P = 0.013. CONCLUSION PET-2 response-adapted strategy could not achieve EFS of 85% in aHL. However, escalated therapy improved outcomes in PET-2-positive patients compared with historical data. TRIAL REGISTRATION CTRI/2012/06/002741 (http://www.ctri.nic.in) and NCT01304849 (http://www.clinicaltrials.gov).
Collapse
Affiliation(s)
| | | | | | | | | | - K Udupa
- Department of Medical Oncology
| | | | | | | | - S Rajaraman
- Department of Tumor Registry, Cancer Institute (WIA), Chennai, India
| | | | | |
Collapse
|
25
|
Brämswig JH, Riepenhausen M, Schellong G. Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study. Lancet Oncol 2015; 16:667-75. [PMID: 25959806 DOI: 10.1016/s1470-2045(15)70140-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND Little is known about parenthood in women who were treated for Hodgkin's lymphoma during childhood and adolescence. We aimed to assess the frequency of parenthood in female survivors of Hodgkin's lymphoma younger than 18 years at diagnosis, and to compare it with that in a female population control group. METHODS In this prospective, longitudinal study, our cohort consisted of 590 female patients younger than 18 years at diagnosis who participated in one of five Hodgkin's lymphoma treatment studies between June 19, 1978, and July 12, 1995. Women who had been followed up for 5 years or longer, were in continuous complete remission, and had no second malignancy or Hodgkin's lymphoma relapse before parenthood were included in our parenthood analysis. Parenthood was defined as the delivery of a liveborn child. Frequency of parenthood was compared with that in the German female population aged 16-49 years, using data from the 2012 Mikrozensus population survey. We assessed parenthood by estimating cumulative incidences and hazard ratios (HRs) with associated variables. FINDINGS 467 of 590 patients in our cohort had long-term follow-up (median 20·4 years [IQR 16·3-24·8]) and were in continuous complete remission. 228 (49%) of 467 patients had 406 children (median of 1·78 children per mother, range 1-7). Cumulative incidences of parenthood were 67% (95% CI 64-75) at 27·7 years of follow-up (the longest number of years that a patient was followed up before she had her first child) and 69% (61-74) at 39·8 years of age (the oldest age of a patient before she had her first child). The incidence of parenthood did not differ between our cohort and the female German population for any age group up to 49 years, except for the 66 women aged 40-44 years at the time of last information, who had a significantly lower frequency of parenthood compared with the general population (40 [61%] of 66 vs 2,208,000 [78%] of 2,847,000; p=0·001). Procarbazine in cumulative doses up to 11,400 mg/m(2), cyclophosphamide in cumulative doses up to 6000 mg/m(2), alkylating agent dose scores of 1-5, therapy group based on disease stage at diagnosis, abdominal and supradiaphragmatic radiation, and age at treatment had no significant or only minor effects on parenthood. Parenthood was significantly reduced in survivors receiving pelvic radiation compared with those who received abdominal and supradiaphragmatic radiation (HR 0·76, 95% CI 0·61-0·95; p=0·01). INTERPRETATION The results of this study document an overall favourable prognosis for parenthood in female survivors of Hodgkin's lymphoma. They will assist counselling of female survivors about their positive potential for future parenthood. FUNDING Deutsche Kinderkrebsstiftung, Jens-Brunken-Stiftung für Leukämie und Lymphomforschung, and Kinderkrebshilfe Münster.
Collapse
Affiliation(s)
- Jürgen H Brämswig
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Albert-Schweitzer-Campus 1, Münster, Germany.
| | - Marianne Riepenhausen
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Albert-Schweitzer-Campus 1, Münster, Germany
| | - Günther Schellong
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Albert-Schweitzer-Campus 1, Münster, Germany
| |
Collapse
|
26
|
|
27
|
Rinne ML, Wen PY. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Williston Park) 2015; 29:265-275. [PMID: 25952491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
28
|
Levin VA. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV. Oncology (Williston Park) 2015; 29:264-268. [PMID: 25952490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
29
|
Abstract
BACKGROUND Hodgkin lymphoma (HL) in children constitutes approximately 30% of all pediatric lymphomas in Sweden. The chance of cure is high, but the frequency of late effects has been considerable. Over recent years, efforts have been made to reduce treatment with maintained survival. MATERIAL AND METHODS All patients 0-17 years, identified in the Swedish Childhood Cancer Register as diagnosed between 1985 and 2009, were included. The material was analyzed using descriptive statistics and for survival estimates the Kaplan-Meier method was used. RESULTS Three hundred and thirty-four patients were identified during this time period. The median age was 14 years. Male sex was over-represented, especially in lower age groups and in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). In nodular sclerosis and in age group 15-17 years, female sex dominated. Most of the cases presented in stages I or II. B-symptoms were present in 38% of cHL, but only in 7% of NLPHL. The number of patients receiving radiotherapy has been significantly reduced during the period studied. The relapse rate in cHL was 10 ± 2% and in NLPHL 16 ± 7%. The relapse rate was significantly higher in cHL stage IIB compared to other stages in the same therapy group. In cHL 6% died, and in NLPHL 0%. The 5-, 10- and 20-year overall survival estimates in cHL were 96 ± 1%, 95 ± 1% and 90 ± 3%, respectively, with no significant difference when comparing different treatment regimens and time periods. The 5- and 10-year overall survival after relapse in cHL was 81 ± 8% and 75 ± 10%, respectively. CONCLUSION During the period studied there is no indication of a decline in survival despite changes in treatment. Survival rates in Sweden are high, and even after relapse chances of cure are high. We were not able to identify any characteristics specific for the group of patients that did not survive.
Collapse
Affiliation(s)
- Annika Englund
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
- Correspondence: A. Englund, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. E-mail:
| | - Charlotte Hopstadius
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
| | - Gunilla Enblad
- Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
| | - Göran Gustafsson
- Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden
| | - Gustaf Ljungman
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
| |
Collapse
|
30
|
Filatova LV. [The effectiveness and toxicity of therapy in primary Hodgkin's lymphoma with extranodal lesions]. Vopr Onkol 2015; 61:214-219. [PMID: 26087601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Using of radiochemotherapy improves short-term and long-term results of treatment in patients with primary Hodgkin's lymphoma (HL) comparing with treatment by chemotherapy alone. The rates of 5-year, 10-year OS and DFS are 88%, 83% and 90%, 86% in case of radiochemotherapy, versus 73%, 66% and 72%, 68% using chemotherapy alone. The 5-year and 10-year OS, DFS estimates in treatment with ABVD are 84% and 83%, 75% and 74%; BEACOPP-baseline--83% and 82%, 82% and 81% (p < 0.05). At the same time ABVD chemotherapy develops less toxicity (p < 0.001). The treatment with 6 cycles of ABVD is considered as the most appropriate in primary Hodgkin's lymphoma patients with extranodal lesions. Using more than 6 cycles doesn't seem to improve OS and DFS (the 5-year and 10-year DFS, OS estimates are 79% and 72%, 80% and 77% versus 88% and 87%, 90% and 89% (p < 0.05). Comparison of complications rate during chemotherapy with MOPP (919 cycles), ABVD (1300 cycles), BEACOPP-baseline (584 cycles), BEACOPP-escalated (140 cycles) reveals major hematologic toxicity and infectious complications rate in BEACOPP-escalated program (p < 0.05).
Collapse
|
31
|
Datsenko PV, Panshin GA. [Hodgkin's lymphoma and radiotherapy]. Vopr Onkol 2015; 61:45-51. [PMID: 26016145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
After a median observation time of 4,5 years, 440 patients with Hodgkin's lymphoma stage I-IV to the Ann Arbor classification were treated with radiotherapy (2200 lymph areas) and ABVD (n=204) or BEACOPP (n=117) or CEA/ABVD (lomustine, etoposide, adriamycine, bleomycine, vinblastine and dacarbacine; n=119) regimens in 1995-2012. Correct allocation of groups with "CR or PR ≥80%" and "PR: 0-79%", after first-line chemotherapy, is extremely important for following RT planning. Adaptation of patients with Hodgkin's lymphoma can take place only after successful treatment, the probability of relapse and fear of repeated courses strongly interfere with this process, especially in the first years after its closure. Duration of remission period, especially in young people, is no less important than the criteria for overall survival. It is impossible to build recommendations for treatment for Hodgkin's lymphoma, based only on long-term survival rates. Importance of radiotherapy in reducing the number of relapses is undeniable, so the idea that the development of the role of chemotherapy in the treatment of the ray method Hodgkin's lymphoma gradually becomes secondary is in serious doubt. Our findings suggest the importance of both maintaining a high disease-free survival and reducing long-term complications in designing treatments of Hodgkin's lymphoma.
Collapse
|
32
|
Nagai H. [Treatment strategy of Hodgkin lymphoma]. Rinsho Ketsueki 2014; 55:1941-1951. [PMID: 25297759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
33
|
Danielewicz I, Małkowski B, Zaucha R, Zalewska M, Leśniewski-Kmak K, Zaucha JM. Early treatment intensification with escalated BEACOPP in patients with Hodgkins lymphoma not responding to ABVD therapy. Acta Oncol 2014; 53:286-8. [PMID: 24304391 DOI: 10.3109/0284186x.2013.862344] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
34
|
Janjetovic S, Janning M, Daukeva L, Bokemeyer C, Fiedler W. Chylothorax in a patient with Hodgkin's lymphoma: a case report and review of the literature. Tumori 2013. [PMID: 24158090 DOI: 10.1700/1334.14813] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Chylothorax is defined as chyle entering the pleural space. The most common causes of chylothorax are lymphoma followed by bronchogenic carcinoma and trauma. CASE REPORT We report a case of chylothorax in a patient with Hodgkin's lymphoma. A 28-year old man was admitted to the hospital with exertional dyspnea and dry cough. A chest X-ray showed the large opacity on the left side suggesting to the presence of pleural effusion. METHODS The effusion was drained, and biochemical tests of the pleural fluid revealed high contents of triglycerides and, hence, confirmed the diagnosis of chylothorax. Cytology of the pleural fluid showed no evidence of Hodgkin's cells. Computer tomography scans of the chest and abdomen exhibited the presence of a soft tissue mass located in the left mediastinum. Mediastinal mass biopsy led to diagnosis of Hodgkin's lymphoma of the nodular sclerosis subtype. The patient received the standard treatment with two cycles of chemotherapy with prednisolone, doxorubicin, cyclophosphamide, vincristine, bleomycin, procarbazine, and etoposide (BEACOPP), followed by an additional two cycles of therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). RESULTS After one cycle of chemotherapy, chylothorax initially decreased. Unfortunately, during the following courses of chemotherapy, the pleural effusion reoccurred and repeated pleural taps were necessary. According to the treatment protocol, radiation of the mediastinal bulk was performed after chemotherapy. Now, nearly one year after completion of radiotherapy, the chylothorax has significantly regressed and no further thoracocenteses were necessary. CONCLUSION The case reveals an example of left-sided chylothorax as the first manifestation of Hodgkin's lymphoma in a young patient. In this case, radiotherapy was shown to be an effective treatment option for lymphoma-associated chylothorax unresponsive to chemotherapy.
Collapse
|
35
|
Aoki H, Ogura R, Tsukamoto Y, Okada M, Natsumeda M, Isogawa M, Yoshida S, Fujii Y. Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution. Neurol Med Chir (Tokyo) 2013; 53:797-804. [PMID: 24162244 PMCID: PMC4508721 DOI: 10.2176/nmc.oa2013-0195] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Accepted: 08/14/2013] [Indexed: 11/20/2022] Open
Abstract
The efficacy and toxicity of high-dose methotrexate (HD-MTX)-based chemotherapy were retrospectively reviewed in patients with primary central nervous system lymphoma (PCNSL). All immunocompetent patients with histologically or radiographically diagnosed PCNSL treated between 2006 and 2012 at Niigata University Hospital were enrolled. Thirty-eight patients with a diagnosis of PCNSL were treated with one of two regimens during different time periods. During the first period, from 2006 to 2009, three 3-week cycles of MPV (MTX + procarbazine + vincristine) were administered (MPV3 group). In the second period, from 2010 to 2012, five 2-week cycles of MTX were administered (MTX5 group). High-dose cytarabine was used in both groups following HD-MTX-based chemotherapy. Whole-brain radiotherapy was used for patients who did not attain a complete response (CR) based on magnetic resonance images. In the MPV3 group, 20 out of 23 patients (87%) completed the planned treatment. The CR rate after chemotherapy was 30%, and 57% after radiation therapy. Thirteen out of 15 patients (87%) in the MTX5 group completed the planned treatment. The CR rates after chemotherapy and radiation therapy were 53% and 93%, respectively. Renal dysfunction was assessed by measuring creatinine clearance rates, which were very similar in both groups. In terms of hematologic toxicity and other adverse reactions, there was no significant difference between the two groups. In conclusion, dose-dense MTX chemotherapy improved outcome with acceptable toxicity compared with the treatment schedule for three cycles of MPV treatment.
Collapse
Affiliation(s)
- Hiroshi Aoki
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| | - Ryosuke Ogura
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| | - Yoshihiro Tsukamoto
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| | - Masayasu Okada
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| | - Manabu Natsumeda
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| | - Mizuho Isogawa
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| | - Seiichi Yoshida
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| | - Yukihiko Fujii
- Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Niigata
| |
Collapse
|
36
|
Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2013; 12:141-7. [PMID: 17454195 DOI: 10.1080/10245330600954072] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
We have evaluated the best method to assess the ovarian reserve and the ovarian protective effect of GnRH-analog (GnRH-a), in 29 women with Hodgkin's disease (HD) treated with chemotherapy (CHT). The ovarian reserve was studied by measuring the serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), inhibin B, antimullerian hormone (AMH) and the ultrasound antral follicular count (AFC). The patients were randomly treated with or without GnRH-a. At the time of study menstrual function was normal in 21 cases (72.4%), but absent in 8 (27.5%). Mean basal values of FSH, LH, AMH, inhibin B and AFC were normal in patients less than 30 years old and in the group treated four years or less before observation. AFC appeared to be the best marker of reduced ovarian reserve and a combination of AFC-AMH or inhibin B appeared the best predictor. In the GnRH-a group, no women had amenorrhoea, although ovarian reserve assessment was not significantly different from those who were not treated. The time-interval from CHT was the only significant predictor of ovarian function in GnRH-a treated patients. In conclusion, ovarian reserve evaluation, in young patients treated by CHT, can be performed by AFC. GnRH-a treatment does not have a protective effect, but could delay the development of ovarian failure.
Collapse
Affiliation(s)
- Loverro Giuseppe
- Department of Obstetric and Gynecology, University of Bari, Policlinico of Bari, Italy
| | | | | | | | | | | |
Collapse
|
37
|
Cao H, Yamamoto K, Yang LX, Weber R. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma. Anticancer Res 2013; 33:3879-3885. [PMID: 24023323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Hodgkin lymphoma (HL) is characterized by malignant Reed-Sternberg cells which express CD30. Current National Comprehensive Cancer Network guidelines for patients with advanced HL (stage III/IV disease) recommend adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), or escalated bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) as first-line regimens. ABVD appears to be as effective, with fewer side effects, as escalated BEACOPP. Escalated BEACOPP leads to a greater progression-free survival but no difference in overall survival. Recent advancements in technology have enabled an exciting shift to molecular-targeted cancer therapy. Brentuximab vedotin, a CD30-directed antibody conjugate, specifically targets malignant HL cells. It is approved by the Food and Drug Administration for the treatment of systemic anaplastic large-cell lymphoma and refractory HL that has progressed after autologous stem cell transplant, or after two prior multiagent chemotherapy regimens among patients ineligible to receive a transplant.
Collapse
Affiliation(s)
- Huynh Cao
- Radiobiology Laboratory, California Pacific Medical Center Research Institute, #602, OPR Bldg, 3801 Sacramento Street, San Francisco, CA 94118, U.S.A.
| | | | | | | |
Collapse
|
38
|
Bozdağ SC, Tekgündüz E, Durgun G, Sarıca A, Demiriz IŞ, Koçubaba S, Altuntaş F. Which regimen is better for stem cell mobilization of lymphoma patients? Transfus Apher Sci 2013; 48:407-10. [PMID: 23643475 DOI: 10.1016/j.transci.2013.04.027] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Although chemotherapy combined with G-CSF is an effective method for hematopoietic stem cell mobilization, standard chemotherapy protocol leading to best stem cell yield is not defined. In our study, we aimed to assess the impact of chemotherapy choice on mobilization outcome in lymphoma patients. Patients were mobilized with cyclophosphamide (n:15), ASHAP (n:11) or VGEPP (n:12) protocols. Groups were similar according to collected CD34+ cell count, total nucleated cell count and median apheresis days. Five out of fifteen (33%) patients could not be mobilized in Cy group but there was only one failed mobilization attempt in both salvage groups (9% with ASHAP vs 8% with VGEPP). In conclusion, we showed that VGEPP and ASHAP are safe protocols in terms of stem cell mobilization and have similar mobilization capacity as cyclophosphamide alone.
Collapse
Affiliation(s)
- Sinem Civriz Bozdağ
- Ankara Oncology Education and Research Hospital, Hematology and Stem Cell Transplantation Clinic, Ankara, Turkey.
| | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
Of a total of 235 Stage I and II Hodgkin's disease patients treated between 1970 and 1979, 103 (43.8 per cent) had mediastinal involvement in 45 of whom the disease was bulky and in 58 non-bulky. This report concentrates on bulky disease patients of whom 45 per cent did not relapse after therapy and 71 per cent are alive. Patients with mediastinal disease were treated with radiotherapy (63), sequential chemo-radiotherapy (37) or chemotherapy alone (3). In the radiotherapy group the relapse rate for bulky disease was significantly higher (65 per cent) than for non-bulky disease (44 per cent) (P less than 0.05) although there was no significant difference in survival. Neither relapse rate nor survival differed significantly in bulky disease patients treated with radiotherapy compared with combined chemo-radiotherapy although there was a 20 per cent difference in relapse-free survival rate in favour of the combined treatment group at five years. Treatments were not allocated randomly and the chemo-radiotherapy group contained a disproportionate number of patients with adverse features (greater than 3 node areas involved, limited lung extension) compared with the irradiated group; 11/25 and 2/17 respectively. The number of lymph node areas involved appeared to influence the relapse rate in the radiotherapy group. There was no correlation between mediastinal mass size and number of node areas involved suggesting that these two features may be independent prognostic factors.
Collapse
|
40
|
|
41
|
Filatova LV, Plotnikova AA, Gershanovich ML, Semiglazova TI. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis]. Vopr Onkol 2013; 59:59-65. [PMID: 23814851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
In a retrospective study during the primary mode MOPP to primary patients LH II/IVAB stages with a poor prognosis rate of CR, 5--and 10-year DFS, OS was 69%, 71% and 68%, 74% and 64%, ABVD--76%, 78%, 83% and 68%, BEACOPP-baseline--73%, 97%, 85% and 82%, respectively. When the program ran BEACOPP-baseline it was revealed higher rates of DFS compared with ABVD and MOPP. Higher OS rates were observed in the primary patients treated with BEACOPP-baseline compared with MOPP (p = 0.04). In terms of DFS and OS MOPP regimen did not differ from ABVD. Program ABVD and BEACOPP-baseline had no differences in terms of OS. The frequency of primary refractory forms of LH did not depend on the conducted regimens of PCT. Significantly less recurrences occurred during the regimen of BEACOPP-baseline compared to MOPP and ABVD. BEACOPP-baseline was accompanied by a more pronounced reversible hematologic toxicity. Against the background of the program BEACOPP-baseline, neutropenia of III-IV degree was detected in 32%, ABVD--16%, MOPP--13%.
Collapse
|
42
|
Welch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol 2012; 14:1304-11. [PMID: 22952196 PMCID: PMC3452344 DOI: 10.1093/neuonc/nos207] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2012] [Accepted: 07/23/2012] [Indexed: 11/13/2022] Open
Abstract
Up to 20% of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens, automatic de-escalation of care based on age is standard practice outside of tertiary care centers. We performed a retrospective review of all PCNSL patients aged 80 years or older treated at Memorial Sloan-Kettering Cancer Center from 1993 to 2011. Demographic and clinical variables were evaluated as predictors of survival by multivariate analysis. Twenty-three of 24 patients were treated with chemotherapy (92% with high-dose MTX, typically in combination with vincristine and procarbazine). One patient received ocular radiation alone for disease limited to the eyes. Response to treatment was noted in 62.5% of patients; 9 (37.5%) had refractory disease. Median overall survival was 7.9 months (95% confidence interval [CI]: 5.8-53), and median progression-free survival was 6.5 months (95% CI: 4.4-29.5). Two-year survival rate was 33%; 3-year survival rate was 17%. Three patients lived more than 4 years postdiagnosis. Most patients tolerated therapy well, and despite low baseline creatinine clearance, no significant renal toxicity was noted. Response status and deep brain involvement were identified as the most important predictors of survival. Multidrug regimens containing high-dose MTX are feasible and efficacious among the oldest patients, particularly those who achieve a complete response by their fifth treatment cycle. Aggressive therapy should be offered to select patients irrespective of advanced age.
Collapse
Affiliation(s)
| | | | - Lisa M. DeAngelis
- Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York
| |
Collapse
|
43
|
Phipps C, Lee YS, Hwang W. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit. Br J Haematol 2012; 159:113-5. [PMID: 22823109 DOI: 10.1111/j.1365-2141.2012.09234.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Henderson TO, Oeffinger KC, Whitton J, Leisenring W, Neglia J, Meadows A, Crotty C, Rubin DT, Diller L, Inskip P, Smith SA, Stovall M, Constine LS, Hammond S, Armstrong GT, Robison LL, Nathan PC. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 2012; 156:757-260. [PMID: 22665813 PMCID: PMC3554254 DOI: 10.1059/0003-4819-156-11-201206050-00002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2024] Open
Abstract
BACKGROUND Childhood cancer survivors develop gastrointestinal cancer more frequently and at a younger age than the general population, but the risk factors have not been well-characterized. OBJECTIVE To determine the risk and associated risk factors for gastrointestinal subsequent malignant neoplasms (SMNs) in childhood cancer survivors. DESIGN Retrospective cohort study. SETTING The Childhood Cancer Survivor Study, a multicenter study of childhood cancer survivors diagnosed between 1970 and 1986. PATIENTS 14 358 survivors of cancer diagnosed when they were younger than 21 years of age who survived for 5 or more years after the initial diagnosis. MEASUREMENTS Standardized incidence ratios (SIRs) for gastrointestinal SMNs were calculated by using age-specific population data. Multivariate Cox regression models identified associations between risk factors and gastrointestinal SMN development. RESULTS At median follow-up of 22.8 years (range, 5.5 to 30.2 years), 45 cases of gastrointestinal cancer were identified. The risk for gastrointestinal SMNs was 4.6-fold higher in childhood cancer survivors than in the general population (95% CI, 3.4 to 6.1). The SIR for colorectal cancer was 4.2 (CI, 2.8 to 6.3). The highest risk for gastrointestinal SMNs was associated with abdominal radiation (SIR, 11.2 [CI, 7.6 to 16.4]). However, survivors not exposed to radiation had a significantly increased risk (SIR, 2.4 [CI, 1.4 to 3.9]). In addition to abdominal radiation, high-dose procarbazine (relative risk, 3.2 [CI, 1.1 to 9.4]) and platinum drugs (relative risk, 7.6 [CI, 2.3 to 25.5]) independently increased the risk for gastrointestinal SMNs. LIMITATION This cohort has not yet attained an age at which risk for gastrointestinal cancer is greatest. CONCLUSION Childhood cancer survivors, particularly those exposed to abdominal radiation, are at increased risk for gastrointestinal SMNs. These findings suggest that surveillance of at-risk childhood cancer survivors should begin at a younger age than that recommended for the general population. PRIMARY FUNDING SOURCE National Cancer Institute.
Collapse
Affiliation(s)
- Tara O Henderson
- University of Chicago Department of Pediatrics, Section of Hematology, Oncology and Stem Cell Transplantation, 5841 South Maryland Avenue, MC 4060, Chicago, IL 60637, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H. Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Ann Oncol 2012; 23:1254-1259. [PMID: 21926399 DOI: 10.1093/annonc/mdr385] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND From 1999, Norwegian guidelines recommend two escalated (esc) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) followed by six standard (s) BEACOPP for patients with advanced-stage classical Hodgkin lymphoma (HL) with an international prognostic score (IPS) ≥ 4. We evaluated retrospectively the experience with this recommendation at the Norwegian Radium Hospital, also including all IPS 3 patients treated with the same regimen. PATIENTS AND METHODS Forty-seven patients were treated between June 1999 and December 2008. IPS was 3 in 10 patients and ≥ 4 in 37. RESULTS Thirty-five patients received eight cycles of BEACOPP, 12 patients received one to six cycles only, mainly due to toxicity. Sixty percent of patients had dose reductions. With median follow-up of survivors of 89 months, 5-year progression-free and overall survival are 84% [95% confidence interval (CI) 73% to 95%] and 91% (95% CI 82% to 100%), respectively. Toxicity was considerable with grade 3 or more infections/febrile neutropenia in 66% of patients, including one death and three cases of Pneumocystis jiroveci pneumonia. Of note, 10 patients (21%) experienced symptomatic aseptic osteonecrosis, of whom 3 have had hip replacement surgery after treatment. CONCLUSION Two escBEACOPP plus six sBEACOPP is efficacious in advanced-stage high-risk HL. We document a high incidence of aseptic bone necrosis, possibly related to prednisolone.
Collapse
Affiliation(s)
- A Fosså
- Department of Oncology, Division of Surgery and Cancer Medicine.
| | - I H Fiskvik
- Department of Oncology, Division of Surgery and Cancer Medicine
| | - A Kolstad
- Department of Oncology, Division of Surgery and Cancer Medicine
| | - G F Lauritzsen
- Department of Oncology, Division of Surgery and Cancer Medicine
| | - E Aurlien
- Department of Oncology, Division of Surgery and Cancer Medicine
| | - A K Blystad
- Department of Oncology, Division of Surgery and Cancer Medicine
| | | | - I M Ikonomou
- Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
| | - H Holte
- Department of Oncology, Division of Surgery and Cancer Medicine
| |
Collapse
|
46
|
Koga Y, Kumagai M, Takimoto T, Mimaya JI, Nakazawa A, Horibe K, Kobayashi R, Tsurusawa M, Inada H, Mori T. [Retrospective analysis of 157 patients with pediatric Hodgkin lymphoma in Japan: investigation by four pediatric cancer study groups]. Rinsho Ketsueki 2012; 53:443-449. [PMID: 22687978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Hodgkin lymphoma is an easily curable malignancy in the pediatric age group and is less frequently observed in Japan. No study with a large sample size of Japanese patients has been conducted. From 1985 to 2000, 157 Japanese patients with Hodgkin lymphoma were retrospectively analyzed based on their clinical characteristics, treatment regimen, and treatment outcome by 4 pediatiric cancer study groups. There were 107 male and 50 female patients with a median age of 10 years 1 month (range: 1 year 8 months to 17 years 8 months). Clinical stage I lymphoma was observed in 37 patients, stage II in 62, stage III in 40, and stage IV in 18. Fifty patients presented with B symptoms (32%). Most patients (n=125, 82%) received more than 6 courses of combination chemotherapy mainly comprising cyclophosphamide, vincristine, procarbazine, prednisolone (COPP), doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The 5-year overall and event-free survival rates were 81.5% and 94.8%, respectively. High-risk disease and age (>10 years) were considered to be poor prognostic factors.
Collapse
Affiliation(s)
- Yuhki Koga
- Japanese Pediatric Leukemia/Lymphoma Study Group
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Tarasenkova AA, Filatova LV, Gershanovich ML, Semiglazova TI. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis]. Vopr Onkol 2012; 58:101-109. [PMID: 22629838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
In this retrospective clinical study 100 patients with primary unfavorable prognosis stage II Hodgkin lymphoma (HL) (n = 50) or stage IV HL (n = 50). The ABVD chemotherapy allowed to achieve remission in 90% of cases with 5-year relapse-free survival (RFS) and overall survival (OS) of 64% and 92%, the basic BEACOPP regimen lead to the same 90% remission rate with 74% DFS and 94% OS. These results for ABVD and basic BEACOPP regimens are characterized by similar statistic values (p = 1.0; p = 0.6; p = 0.9), although the use basic BEACOPP lead to statically valid decrease of grade III-IV toxicity (p = 0.005). The occurrence of primary refractory HL was slightly higher in basic BEACOPP group (18% versus 10% in ABVD group), although this difference had no statistical value (p = 0.3) and was probably due to higher number of patients with > 1 extranodal localizations. The occurrence of primary refractory HL correlated to disease stage: 6% in stage II and 22% in stage IV (p = 0.04). HL relapse frequency in ABVD and BEACOPP groups was similar (12% and 8%), there was no statistically valid difference (p = 0.5). In ABVD and basic BEACOPP recipients with stage II/IV HL the primary refractory disease rate was 15%, relapse rate was 10%. Five-year OS in primary refractory and relapsed patients was lower, than in general patient population (64% and 70% compared to 80%), although the difference had no statistical significance (p = 0.6, p = 0.7).
Collapse
|
48
|
Datsenko PV, Pan'shin GA, Sotnikov VM, Ivashin AV, Gombolevskiĭ VA, Golub SV, Evstikheev ÉV. [Role of response to first-line chemotherapy and of the primary lesion in Hodgkin lymphoma]. Vopr Onkol 2012; 58:66-70. [PMID: 22629831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Based on the results of combined treatment with inclusion of ABVD and BEACOPP-21 chemotherapy regimens the basic principles of therapy depending on the nodal relaps criterium were developed. The most rational approach to treatment results evaluation concerns the lesions with the least response to chemotherapy. The groups of "adequate" and "inadequate" response to chemotherapy should be formed. The initial lesion localisation doesn't play an important part in the modern chemotherapy settings and should not be concerned while choosing tactics of radiation therapy. The method described should interest oncologists and radiologists involved in the treatment of Hodgkin lymphoma.
Collapse
|
49
|
Filatova LV, Tarasenkova AA, Gershanovich ML, Semiglazov TI. [Relapse in Hodgkin lymphoma]. Vopr Onkol 2012; 58:265-274. [PMID: 22774536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The retrospective study revealed the 15% relapse rate in patients with stage II-IV unfavorable prognosis Hodgkin lymphoma, 5-year OS in relapsed patients was 84%. Karnofsky score less than 80 (p=0,0001), more than 1 extranodal lesion (p=0,0004), extensive (equal to stage III-IV) involvement on relapse (p=0,001), b-symptoms on relapse (p=0,023), more than 5 lymph nodal lesions (p=0,027), albumin level less than 40 g per liter (p=0,037), detection of new nodal lesions (p=0,041) were shown by discriminative analysis as the therapy effect predictors in patients with Hodgkin lymphoma relapse. In patients with second-line therapy failure the actuarial survival rate was lower by 55% in comparison to patients with chemosensitive relapses (40% and 95%). The secondary therapy resistance was shown to be an unfavorable prognosis predictive factor (p=0,0001). The multifactorial overall survival analysis revealed the following adverse prognostic factors: failure of second-line treatment (p=0,0001), first early relapse (p=0,01), albumin level on relapse less than 40 g per liter (p=0,02), use of standard chemotherapy instead of irradiation (p=0,02). The relapse patients with 1 or less risk factors had 95% 5-year OS, the patients with 3 or more adverse risk factors had 70% OS (p=0,0002). The lowest 10-year OS was observed in patients with 2 or more adverse risk factors, 48% and 28% accordingly. Adverse risk factors must be considered while choosing the optimal treatment strategy aimed at better survival rate.
Collapse
|
50
|
Datsenko PV, Pan'shin GA, Sotnikov VM, Ivashin AV, Evstikheev ÉV, Golub SV, Gombolevskiĭ VA. [The optimal total focal radiotherapy dosage after first-line chemotherapy in patients with Hodgkin lymphoma]. Vopr Onkol 2012; 58:527-531. [PMID: 23607209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Based on the treatment results of 300 Hodgkin lymphoma patients the authors formulated the basic approaches for radiation treatment in ABVD and BEACOPP-21 chemotherapy regimens recipients. In patients with complete response to chemotherapy any dose regimen (26 to 44 Gr) leads to 100% local disease control. In patients with major response to chemotherapy (PR> or =80%) the 36 Gr total focal dose allows an adequate local control, more intensive local control doesn't yield better results. In patients with PR 0-79% the implication of total focal doses less than 40 Gr leads to statistically significant increase of nodal relapse rate. These treatment approaches may be implied by specialists conducting chemotherapy and radiation therapy in Hodgkin lymphoma patients.
Collapse
|